Cell Therapeutics Price Target Raised to $6.00 at Roth Capital (CTICD)
Equities research analysts at Roth Capital raised their price target on shares of Cell Therapeutics (NASDAQ:CTICD) from $4.50 to $6.00 in a research note issued to investors on Thursday, American Banking & Market News reports.
Cell Therapeutics, Inc (NASDAQ:CTICD) develops, acquires and commercializes treatments for cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.